Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The integrated CRDMO platform added 209 new integrated projects throughout the year, with approximately half originating from the U.S. market, bringing the total number of integrated projects to a record 945. Among different molecule types, bispecific and multispecific antibodies contributed nearly 20% of the group's total revenue, representing a year-on-year increase of over 120%. With the continued execution of the "Follow and Win the Molecule" strategy, the combined number of Phase III clinical and commercial manufacturing projects reached 99, indicating potential for accelerated growth in the commercial manufacturing business. Research service business achieved record highs in both upfront and total payment amounts, with the total potential milestone payments for last year's collaborative projects exceeding $4 billion. WUXI BIO is accelerating its global footprint; after establishing a presence in China, the U.S., Ireland, Germany, and Singapore, it has now entered Qatar to serve the Middle East market. Leveraging its industry-leading digital CRDMO solutions, the company aims to deliver an exceptional customer experience and superior delivery efficiency. The aforementioned materials indicate that WUXI BIO anticipates achieving accelerated growth in 2026.